Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in patients with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, and since 2024 for cardiovascular risk reduction in patients with established cardiovascular disease and overweight or obesity
CJC-1295 was structurally modified with Drug Affinity Complex (DAC) technology or formulated without DAC (often referred to clinically as modified GRF 1-29) to extend its bioavailability and signaling duration
It provides 500 mg per serving, which is an ideal dose for supporting collagen formation and antioxidant activity without overloading the system
However, they must be used under the guidance of qualified healthcare professionals, as individual responses vary and careful monitoring is essential
Plaintiffs argue that the manufacturers knew or should have known about these risks based on clinical data, adverse event reports, medical literature, and post-market safety information
PLoS ONE 2018, human dorsal-root-ganglion neurons: GLP-1R agonists do not excite nociceptors directly and have no effect on capsaicin/TRPV1 responses but enhance ATP/P2X signaling, so TRPV1 is excluded as the channel
